By Connor Hart
Scholar Rock named David Hallal as its chief executive, succeeding Jay Backstrom.
Hallal, who has served as chairman of the biopharmaceutical company's board since 2017, previously spent more than a decade holding executive positions at Alexion.
In the transition, Backstrom will move an advisory role and continue working with the company's executive team and board, Scholar Rock said Monday.
With the CEO transition, Scholar Rock said that Vikas Sinha will join as chief financial officer, R. Keith Woods has been appointed chief operating officer and Akshay Vaishnaw was named president of research and development.
Sinha formerly served as chief financial officer of Alexion and ElevateBio.
In the chief operating role, Woods will focus on evolving the company into what it called a fully-integrated global enterprise. He previously was chief operating officer of Argenx.
Vaishnaw will serve in the newly created role of president of research and development after previously serving as president of Alnylam.
Shares fell 1.5%, to $32.31, in pre-market trading.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
April 28, 2025 07:10 ET (11:10 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。